When sunitinib was given as an adjuvant therapy in renal cell carcinoma, patients reported worse symptoms and lower health-related quality of life scores.
Stereotactic body radiation therapy (SBRT) may be a safe and effective therapeutic option that couold provide localized control.
The impact of switching to or continuing treatment with systemic therapy post-stereotactic radiosurgery in renal cell carcinoma requires further study.
A meta-analysis compared outcomes between the use of partial nephrectomy using a robotic surgical approach and open or laparoscopic partial nephrectomy.
Nonsurgical treatment of small tumor renal cancer may be as effective as radical nephrectomy but with fewer complicationsAugust 22, 2018
Renal stage carcinoma (RCC) has relatively low mortality rates with respect to cancer diagnoses, as the disease tends to be slow growing.
Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell CarcinomaAugust 03, 2018
Circulating blood biomarkers related to angiogenesis may help clinicians predict who will have a robust response to sunitinib.
Research focused on renal cell carcinoma appears to confirm the potential etiologic role of vitamin D binding protein in cancer.
Any new study of pazopanib or sunitinib must be placed in perspective of the changing treatment landscape and the market entrance of new immunotherapies.
Obesity is associated with an increased likelihood of clear cell and possibly chromophobe renal cell carcinoma.
The association between obesity, age, and renal cell carcinoma prognosis requires additional investigation.
The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on tumor characteristics especially challenging.
Findings previously demonstrated that nivolumab plus ipilimumab prolongs overall survival and was better tolerated among patients with renal cell carcinoma, but its impact on health-related quality of life was not reported.
Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the findings at the ASCO 2018 meeting.
The incorporation and efficacy of targeted therapies to management has called into question the conventional standard of using cytoreductive nephrectomy prior to sunitinib.
Researchers assigned 38 patients with metastatic renal cell carcinoma to receive pegilodecakin plus nivolumab or pembrolizumab.
Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.
An example of where biomarkers may help to select the best medication for a patient and also assist in drug development is the tyrosine kinase inhibitor (TKI) dovitinib for renal cell carcinoma (RCC).
The phase 3 METEOR study previously demonstrated that cabozantinib significantly improved survival outcomes among patients with relapsed renal cell carcinoma.
Recent research indicates that there were no significant differences in the genomic landscape of clear cell RCC primary tumors and metastases, or between the different sites of metastases.
Immunotherapy may supplant sunitinib in RCC, except for in patients who cannot tolerate checkpoint inhibition.
Approval was based on results from the randomized phase 3 CheckMate-214 study.
The standard schedule is associated with AEs including grade 3 to 4 fatigue, HFS, and diarrhea.
Several phase 3 clinical trials are likely to identify new frontline standards of care.
Previous studies showed that combination therapy with nivolumab and ipilimumab has promising efficacy for various cancers, including RCC, compared with either agent alone.
VEGF and PD-1 pathway inhibitors show promising improvements compared with single-agent VEGF pathway inhibitors.
Access a treatment regimen chart with detailed information for renal cell carcinoma, including tyrosine kinase inhibitors and cytokine therapy.
Researchers enrolled 6 and 49 patients into dose-finding and dose expansion stages, respectively.
Previous studies found that an elevated pH environment leads to nearly a 40% reduction in pazopanib exposure.
Close to 60% of all patients with VHL will develop RCC or renal cysts.
A shift toward multidisciplinary care is inevitable for the treatment of locally advanced and metastatic RCC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC